Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

Watch TheBody.com's HIV and Aging Expert Nelson Vergel interview Dr. Stephen Grinspoon, Professor at Harvard Medical School and the Director of a Program in Nutritional Metabolism at Massachusetts General Hospital about the causes of body shape changes in HIV -- and most importantly, what you can do about them.

Published
24 August 2016
From
The Body
Tanzania: ARVs Now for Any CD4 Count

People living with HIV would from October start anti-retroviral treatment straightaway given any CD4 cell count upon testing, the government has announced.

Published
24 August 2016
From
AllAfrica
German medicines watchdog rejects ‘new tenofovir’ pill

The German health technology assessment agency IQWiG has announced that it finds no advantage in Descovy, a combination pill containing a new version of the HIV

Published
22 August 2016
By
Gus Cairns
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven

When investigators reviewed Emtricitabine/tenofovir alafenamide in HIV infection, they found that partly no data were available, and partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group, they conclude.

Published
19 August 2016
From
German Institute for Quality and Efficiency in Health Care
German agency criticises European programme for speeding some drug approvals

In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.

Published
18 August 2016
From
STAT
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®), as treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

Published
16 August 2016
From
ViiV press release
Most people taking second-line ART in sub-Saharan Africa achieve viral suppression but there's a need for third-line treatment options

Approximately 85% of people switched to protease inhibitor-based second-line antiretroviral (ART) in sub-Saharan Africa achieve and maintain an undetectable viral load with their new regimen, according to research

Published
12 August 2016
By
Michael Carter
Can immunotherapy cure HIV?

HIV cure researchers and advocates met at Fred Hutchinson Cancer Research Center last week to explore whether immunotherapy — treatments that harness the immune system to fight cancer — could play a role in bringing about a cure or a long-term remission for HIV, the virus that causes AIDS.

Published
10 August 2016
From
Fred Hutch News Service
Efavirenz appears to be associated with elevated suicide risk in START trial

Participants in the START treatment-timing trial who took antiretroviral regimens containing efavirenz had an increased risk of suicidal and self-injuring behaviour than those not using efavirenz, though

Published
10 August 2016
By
Liz Highleyman
Package of prophylaxis against infections reduces the risk of death for people starting HIV treatment very late

A package of enhanced prophylaxis against infections significantly reduced the risk of death in adults and children with advanced HIV disease after starting antiretroviral treatment in a

Published
08 August 2016
By
Keith Alcorn
← First12345...424Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close